TNFA Stock Overview
A clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TNF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.15 |
| 52 Week High | US$6.76 |
| 52 Week Low | US$1.05 |
| Beta | 2.54 |
| 1 Month Change | 1.38% |
| 3 Month Change | -25.81% |
| 1 Year Change | -81.74% |
| 3 Year Change | -99.26% |
| 5 Year Change | n/a |
| Change since IPO | -99.23% |
Recent News & Updates
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01
We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Shareholder Returns
| TNFA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.9% | -1.9% | -2.8% |
| 1Y | -81.7% | 2.7% | 24.1% |
Return vs Industry: TNFA underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: TNFA underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| TNFA volatility | |
|---|---|
| TNFA Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TNFA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TNFA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 6 | n/a | tnfpharma.com |
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.
TNF Pharmaceuticals, Inc. Fundamentals Summary
| TNFA fundamental statistics | |
|---|---|
| Market cap | US$3.17m |
| Earnings (TTM) | -US$28.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs TNFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNFA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.92m |
| Earnings | -US$28.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TNFA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 13:56 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TNF Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|